Happi-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastrointestinal motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective relief from acid-related disorders including gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The sustained-release (SR) formulation of Happi-L Capsule ensures prolonged therapeutic plasma concentrations, optimizing symptom control and improving patient compliance by reducing dosing frequency. This combination is particularly beneficial in conditions where impaired gastric motility coexists with hyperacidity, offering synergistic effects to enhance gastrointestinal comfort and mucosal healing. Happi-L Capsule SR should be administered under medical supervision, considering contraindications such as hypersensitivity to either component and caution in patients with renal or hepatic impairment. Adverse effects may include mild gastrointestinal disturbances, headache, or dizziness. Regular monitoring and adherence to prescribed dosage are essential to maximize therapeutic outcomes and minimize potential risks.